Threat & Risk Assessment for Biotech & Pharma
Identify, prioritize, and act on security risks across your organization in Biotech & Pharma.
Biotech and pharmaceutical organizations sit at the intersection of two targets that attract the most sophisticated threat actors operating today: high-value intellectual property and deeply sensitive personal information. Proprietary research, drug discovery pipelines, clinical trial data, genomic records, and the personal health outcomes of trial participants are all present in the same environment — carrying materially different risk profiles that a generic security assessment is unlikely to distinguish between.
Nation-state actors and organized criminal groups both pursue biotech organizations, for different reasons. Espionage operations target proprietary research and IP representing years of investment. Ransomware operators target the operational disruption a locked clinical data system or a compromised laboratory network creates — organizations under time pressure to restore research continuity are more likely to pay. Understanding which threat profile is most relevant to your organization, and which assets each type of actor would prioritize, is the starting point for any meaningful risk assessment here.
Privacy Horizon's TRA maps assets across your environment — research systems, clinical trial databases, genomic repositories, CRO partner connections, and the cross-border data governance structures governing international collaborations. That inventory drives a vulnerability analysis examining technical controls, identity and access management, network segmentation between research and corporate environments, and the third-party access pathways academic and contract research partners use.
The risk register distinguishes between IP theft risk, data breach risk, and operational disruption risk — because the mitigations differ, the regulatory consequences differ, and the prioritization needs to reflect what your organization can least afford to have compromised. Provincial health privacy legislation applies to clinical trial participant data in most jurisdictions; PIPEDA governs other categories. A breach in this sector triggers notification obligations and, where research ethics board requirements are relevant, additional disclosure expectations. The remediation roadmap sequences fixes against those priorities — a grounded plan rather than a list of abstract controls.
Why Threat & Risk Assessment matters for Biotech & Pharma
The combination of irreplaceable IP and regulated health data makes biotech and pharma organizations a high-consequence target where the cost of a breach extends well beyond incident response. Exposure of clinical trial participant data carries notification duties and research ethics implications. Loss of proprietary research data can be commercially catastrophic and may be unrecoverable. Supply chain and CRO third-party risk means the exposure doesn't have to originate inside your walls to land on your balance sheet. A TRA gives you a structured, independent view of where those risks are concentrated and what the realistic threat landscape looks like — before an incident forces that clarity on less favorable terms.
Biotech and pharmaceutical organizations handle some of the most sensitive categories of personal information — genetic data, clinical trial records, and health outcomes — alongside high-value intellectual property that is a frequent target of nation-state and criminal threat actors. Regulatory scrutiny spans data protection law, clinical research ethics requirements, and Health Canada oversight. Research partnerships and global trial networks introduce complex cross-border data governance obligations.
Relevant frameworks: ISO 27001, ISO 27701, SOC 2 Type II, Health-sector privacy legislation (PHIPA-type, provincial), PIPEDA / provincial private-sector privacy laws
Our approach for Biotech & Pharma
Privacy Horizon structures the TRA for biotech and pharma organizations around two parallel tracks: IP protection and health data security. Asset identification maps research systems, clinical databases, and partner connections separately, recognizing that the controls governing each are different and the threat actors interested in each are different. Vulnerability analysis examines network segmentation between research and enterprise environments, third-party CRO access controls, and the data governance structures around genomic and biometric data. The risk register ranks exposures across both tracks by likelihood and impact, and the remediation roadmap sequences fixes to address the highest-consequence gaps first — with clear guidance on what the applicable provincial health privacy legislation and PIPEDA require as a baseline.
What Threat & Risk Assessment includes
A threat and risk assessment (TRA) gives you a clear, prioritized view of where your security risks are and what to do about them first.
Asset & Threat Identification
Map what you're protecting and what threatens it.
Vulnerability Analysis
Find the weaknesses that matter most.
Risk Prioritization
Rank risks by likelihood and impact, not guesswork.
Remediation Roadmap
A practical plan to reduce risk in priority order.
Other services for Biotech & Pharma
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.